- Home
- TRX vs CHRS Comparison
TRX vs CHRS Comparison
Compare TRX & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRX
- CHRS
- Stock Information
- Founded
- TRX 1990
- CHRS 2010
- Country
- TRX Canada
- CHRS United States
- Employees
- TRX N/A
- CHRS N/A
- Industry
- TRX
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TRX
- CHRS Health Care
- Exchange
- TRX Nasdaq
- CHRS Nasdaq
- Market Cap
- TRX 228.9M
- CHRS 195.3M
- IPO Year
- TRX N/A
- CHRS 2014
- Fundamental
- Price
- TRX $0.63
- CHRS $1.68
- Analyst Decision
- TRX Strong Buy
- CHRS Strong Buy
- Analyst Count
- TRX 1
- CHRS 4
- Target Price
- TRX $1.10
- CHRS $4.51
- AVG Volume (30 Days)
- TRX 3.6M
- CHRS 1.0M
- Earning Date
- TRX 11-28-2025
- CHRS 11-06-2025
- Dividend Yield
- TRX N/A
- CHRS N/A
- EPS Growth
- TRX N/A
- CHRS N/A
- EPS
- TRX N/A
- CHRS 1.55
- Revenue
- TRX $47,731,000.00
- CHRS $272,209,000.00
- Revenue This Year
- TRX $23.64
- CHRS N/A
- Revenue Next Year
- TRX $51.77
- CHRS $109.48
- P/E Ratio
- TRX $604.90
- CHRS $3.29
- Revenue Growth
- TRX 29.98
- CHRS 52.33
- 52 Week Low
- TRX $0.27
- CHRS $0.66
- 52 Week High
- TRX $0.85
- CHRS $2.43
- Technical
- Relative Strength Index (RSI)
- TRX 45.37
- CHRS 52.98
- Support Level
- TRX $0.62
- CHRS $1.64
- Resistance Level
- TRX $0.69
- CHRS $1.81
- Average True Range (ATR)
- TRX 0.05
- CHRS 0.10
- MACD
- TRX -0.02
- CHRS -0.02
- Stochastic Oscillator
- TRX 4.39
- CHRS 34.63
About TRX TRX Gold Corporation
TRX Gold Corp is a mineral resource company. It is engaged in the acquisition of interests and the exploration of natural resource properties. Its mineral properties are located in the United Republic of Tanzania. The company's main area of interest has been in the exploration and development of gold properties. It is focused on the Buckreef Gold Project which comprises five prospects, namely Buckreef, Bingwa, Tembo, Eastern Porphyry, and Buziba.
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.